Antibe Therapeutics, Inc.

Ordinary Shares International Reporting
OTCQX International
Verified Company Profile 11/29/2016
Contact Info
  • 15 Prince Arthur Avenue
  • Toronto, ONT M5R 1B2
  • Canada

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report Sep 30, 2016 Interim Financial Report
CIK 0001583682
Fiscal Year End 3/31
OTC Marketplace OTCQX International
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o
Incorporated In: Canada
Year of Inc. 2013
Employees 45 a/o Mar 27, 2015
Company Officers/Contacts
Daniel Legault CEO
John Wallace CSO
Alain Wilson CFO
Scott Curtis VP, Business Development
David Vaughan Chief Development Officer
Beth Chin Finance Manager
Company Directors
Walt Macnee Chairman
Roderick Flower
Daniel Legault
Samira Sakhia
John Wallace
Service Providers
OTCQX Advisor
Not Available
Accounting/Auditing Firm
Zeifmans LLP Chartered Accountants
201 Bridgeland Avenue
Toronto, ONT, M6A 1Y7

Legal Counsel Investor Relations Firm
Not Available
ATBPF Security Details
Share Structure
Market Value1 $13,009,340 a/o Dec 02, 2016
Authorized Shares Unlimited a/o Nov 28, 2016
Outstanding Shares 93,190,115 a/o Jun 30, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 22,005,858 a/o Aug 22, 2014
Par Value Not Available
Shareholders of Record Not Available
Non US Stock Exchange Listing
ATE - TSX Venture Exchange - Qualified
Short Selling Data
Short Interest 6,000 (100%)
Nov 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security